Human recombinant soluble ACE2 (hrsACE2) shows promise for treating severe COVID­19

• Tarek Mohamed Abd El-Aziz,
• Ahmed Al-Sabi &
• James D. Stockand 

Signal Transduction and Targeted Therapy volume 5, Article number: 258 (2020)

PDF: https://www.nature.com/articles/s41392-020-00374-6.pdf

A recent study by Zoufaly et al. published in The Lancet Respiratory Medicine describes encouraging data from the first severe COVID-19 patient successfully treated with human recombinant soluble angiotensin-converting enzyme-2 (hrsACE2).¹ The published data document upon treatment of an adaptive immune response, the disappearance of the virus swiftly from the serum, the nasal cavity and lungs, and a reduction of inflammatory cytokine levels that are critical for COVID-19 pathology. Notably, the use of hrsACE2 did not impede the generation of neutralizing antibodies, leading to a significant clinical improvement of the treated patient.

https://www.nature.com/articles/s41392-020-00374-6/